Epizyme, Inc. (EPZM): Price and Financial Metrics


Epizyme, Inc. (EPZM): $1.06

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EPZM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 455

in industry

EPZM POWR Grades


  • EPZM scores best on the Value dimension, with a Value rank ahead of 60.18% of US stocks.
  • EPZM's strongest trending metric is Growth; it's been moving down over the last 169 days.
  • EPZM's current lowest rank is in the Momentum metric (where it is better than 4.01% of US stocks).

EPZM Stock Summary

  • Revenue growth over the past 12 months for Epizyme Inc comes in at 192.93%, a number that bests 96.07% of the US stocks we're tracking.
  • The volatility of Epizyme Inc's share price is greater than that of 96.81% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for EPZM comes in at -155.72% -- higher than that of only 2.41% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Epizyme Inc are KMPH, BYSI, LQDA, CLXT, and KPTI.
  • Visit EPZM's SEC page to see the company's official filings. To visit the company's web site, go to www.epizyme.com.

EPZM Valuation Summary

  • In comparison to the median Healthcare stock, EPZM's price/sales ratio is 326.32% higher, now standing at 16.2.
  • EPZM's EV/EBIT ratio has moved up 191.6 over the prior 100 months.
  • EPZM's price/sales ratio has moved up 3.5 over the prior 100 months.

Below are key valuation metrics over time for EPZM.

Stock Date P/S P/B P/E EV/EBIT
EPZM 2021-08-31 16.2 7.8 -2.1 -2.8
EPZM 2021-08-30 15.6 7.5 -2.0 -2.7
EPZM 2021-08-27 15.7 7.6 -2.0 -2.8
EPZM 2021-08-26 15.3 7.3 -1.9 -2.7
EPZM 2021-08-25 15.6 7.5 -2.0 -2.8
EPZM 2021-08-24 15.4 7.4 -1.9 -2.7

EPZM Growth Metrics

    The year over year price growth rate now stands at -58.95%.
  • Its 5 year price growth rate is now at 63.29%.
  • Its 5 year net cashflow from operations growth rate is now at -129.81%.
Over the past 49 months, EPZM's revenue has gone up $23,739,000.

The table below shows EPZM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 34.217 -228.002 -266.704
2021-06-30 32.582 -227.886 -256.943
2021-03-31 22.039 -223.643 -251.031
2020-12-31 15.762 -206.336 -231.694
2020-09-30 11.681 -188.705 -221.863
2020-06-30 13.83 -184.411 -201.879

EPZM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EPZM has a Quality Grade of D, ranking ahead of 24.13% of graded US stocks.
  • EPZM's asset turnover comes in at 0.081 -- ranking 279th of 681 Pharmaceutical Products stocks.
  • MTEX, VTVT, and ADXS are the stocks whose asset turnover ratios are most correlated with EPZM.

The table below shows EPZM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.081 0.731 -0.584
2021-03-31 0.052 0.668 -0.620
2020-12-31 0.036 0.679 -0.669
2020-09-30 0.028 0.722 -0.731
2020-06-30 0.034 0.882 -0.713
2020-03-31 0.044 0.964 -0.691

EPZM Price Target

For more insight on analysts targets of EPZM, see our EPZM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $23.50 Average Broker Recommendation 1.57 (Moderate Buy)

EPZM Stock Price Chart Interactive Chart >

Price chart for EPZM

EPZM Price/Volume Stats

Current price $1.06 52-week high $12.10
Prev. close $1.06 52-week low $1.02
Day low $1.04 Volume 6,803,734
Day high $1.14 Avg. volume 2,845,896
50-day MA $2.72 Dividend yield N/A
200-day MA $5.63 Market Cap 110.13M

Epizyme, Inc. (EPZM) Company Bio


Epizyme, Inc. discovers and develops epigenetic therapies for cancer patients. The company was founded in 2007 and is based in Cambridge, Massachusetts.


EPZM Latest News Stream


Event/Time News Detail
Loading, please wait...

EPZM Latest Social Stream


Loading social stream, please wait...

View Full EPZM Social Stream

Latest EPZM News From Around the Web

Below are the latest news stories about Epizyme Inc that investors may wish to consider to help them evaluate EPZM as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | January 27, 2022

Epizyme announces proposed public offering of shares

Epizyme (NASDAQ:EPZM) intends to offer and sell its shares in an underwritten public offering. EPZM also intends to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered. Epizyme anticipates using the net proceeds from the offering - together with its existing cash, cash...

Seeking Alpha | January 26, 2022

Epizyme Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., January 26, 2022--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the propose

Yahoo | January 26, 2022

Epizyme multiple myeloma candidate granted FDA Orphan Drug Designation

The FDA has granted Orphan Drug Designation to Epizyme (EPZM +1.4%) for a small molecule inhibitor of the enzymatic activity of Su(var) for the treatment of multiple myeloma. The full generic name of the candidate is small molecule inhibitor of the enzymatic activity of Su(var), Enhancer-of-zeste, Trithorax domain containing 2 (SETD2)...

Seeking Alpha | January 19, 2022

Epizyme jumps after product revenue shows strong sequential growth: Q4 Prelim

Epizyme <> reports its preliminary estimate for TAZVERIK product revenue to be $11.2-$11.7M for Q4 2021. TAZVERIK commercial sales is expected to be between $7.0-7.5M, representing…

Seeking Alpha | January 10, 2022

Read More 'EPZM' Stories Here

EPZM Price Returns

1-mo -58.43%
3-mo -74.76%
6-mo -84.01%
1-year -90.68%
3-year -88.90%
5-year -89.56%
YTD -57.60%
2021 -76.98%
2020 -55.85%
2019 299.35%
2018 -50.92%
2017 3.72%

Continue Researching EPZM

Want to see what other sources are saying about Epizyme Inc's financials and stock price? Try the links below:

Epizyme Inc (EPZM) Stock Price | Nasdaq
Epizyme Inc (EPZM) Stock Quote, History and News - Yahoo Finance
Epizyme Inc (EPZM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0849 seconds.